Literature DB >> 7627927

Depot neuroleptic therapy: clinical considerations.

G J Remington1, M E Adams.   

Abstract

The management of schizophrenia is generally a long-term process with neuroleptics representing the cornerstone of treatment. Although not without their own limitations, depot neuroleptics offer an important alternative to oral agents, and they should be routinely considered as an option in any long-term treatment planning. The present article reviews depot neuroleptics, and focuses particularly on clinical considerations pertaining to their use.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7627927

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN： 0706-7437            Impact factor:   4.356


  10 in total

1.  Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.

Authors:  Diana De Graeve; Ann Smet; Angelika Mehnert; Sue Caleo; Houda Miadi-Fargier; Guillermo Jasso Mosqueda; Damien Lecompte; Joseph Peuskens
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

2.  Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.

Authors:  P S Chue; Bart Heeg; Erik Buskens; Ben A van Hout
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

Authors:  Gerd Laux; Bart Heeg; Ben A van Hout; Angelika Mehnert
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 4.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

Review 5.  Long-acting injectable antipsychotics in the elderly: guidelines for effective use.

Authors:  Prakash S Masand; Sanjay Gupta
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

6.  Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database.

Authors:  Tim Lambert; Brett Emmerson; Harry Hustig; Sophie Resseler; An Jacobs; Belinda Butcher
Journal:  BMC Psychiatry       Date:  2012-03-26       Impact factor: 3.630

7.  Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America.

Authors:  Rogelio Apiquian; Rodrigo Córdoba; Mario Louzã
Journal:  Neuropsychiatr Dis Treat       Date:  2010-12-22       Impact factor: 2.570

8.  Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study.

Authors:  Adam J Savitz; Haiyan Xu; Srihari Gopal; Isaac Nuamah; Paulien Ravenstijn; David Hough; Maju Mathews; Yu Feng; Lu Yu; Masayoshi Takahashi; Dennis Liu; Gang Wang; Jin-Sang Yoon; Jiahn-Jyh Chen
Journal:  Neuropsychiatr Dis Treat       Date:  2017-08-17       Impact factor: 2.570

Review 9.  Advances in the delivery of buprenorphine for opioid dependence.

Authors:  Richard N Rosenthal; Viral V Goradia
Journal:  Drug Des Devel Ther       Date:  2017-08-28       Impact factor: 4.162

10.  Partial compliance with long-acting paliperidone palmitate and impact on hospitalization: a 6-year mirror-image study.

Authors:  Sofia Pappa; Katy Mason
Journal:  Ther Adv Psychopharmacol       Date:  2020-05-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.